当前位置: 首页 >> 检索结果
381. The role of prokinetics in managing gastrointestinal involvement in systemic sclerosis: a systematic literature review.
作者: Alberto Ezquerra-Durán.;Luis G Alcala-Gonzalez.;Alfredo Guillen-Del-Castillo.;Carmen P Simeón-Aznar.;Elizabeth Barba.;Carolina Malagelada.;Michael Hughes.;Zsuzsanna H McMahan.
来源: Rheumatology (Oxford). 2025年
Gastrointestinal involvement (GI) in systemic sclerosis (SSc) is frequent and heterogeneous, manifesting with different degrees of dysmotility. This systematic literature review aimed to summarize evidence on prokinetics for treating SSc-related GI dysmotility.
382. Towards the definition of disease phenotypes in pediatric SAPHO syndrome: a national multicentric study.
作者: Caterina Matucci-Cerinic.;Anna Attico.;Clara Malattia.;Alessandro Consolaro.;Silvia Rosina.;Luciana Breda.;Saverio La Bella.;Marco Cattalini.;Francesca Ricci.;Giovanni Conti.;Adele Civino.;Letizia Baldini.;Francesco Licciardi.;Antonella Insalaco.;Francesco La Torre.;Serena Pastore.;Giovanni Filocamo.;Gisella Beatrice Beretta.;Francesca Biscaro.;Angela Miniaci.;Gabriele Simonini.;Edoardo Marrani.;Angela Pistorio.;Nicolino Ruperto.;Stefano Volpi.;Roberta Caorsi.;Gianmaria Viglizzo.;Marco Gattorno.; .
来源: Rheumatology (Oxford). 2025年
To confirm the presence of different disease phenotypes of pediatric SAPHO syndrome (pSAPHO) based on their skin manifestations in a large cohort of Italian patients.
383. Anti-citrullinated procollagen C-endopeptidase enhancer antibody: a potential biomarker for seronegative rheumatoid arthritis.
作者: Hongying Lin.;Yang Xie.;Xihua Wei.;Chaonan Wei.;Zhanguo Li.;Fanlei Hu.
来源: Rheumatology (Oxford). 2025年
Although with great advances, the biomarkers used in the diagnosis of rheumatoid arthritis (RA) are still challenging, especially in seronegative RA. Recently, procollagen C-endopeptidase enhancer (PCOLCE) was revealed as a potential autoantigen of seronegative RA by our group. This study aimed to further analyze the B cell autoantigenic epitopes of PCOLCE and the diagnostic value of its antibody in seronegative RA.
384. A Phase 2 randomised trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis.
作者: Christopher P Denton.;Otylia Kowal-Bielecka.;Susanna M Proudman.;Marzena Olesińska.;Margitta Worm.;Nicoletta Del Papa.;Marco Matucci-Cerinic.;Jana Radewonuk.;Jeanine Jochems.;Adrian Panaite.;Amgad Shebl.;Anna Krupa.;Yannick Allanore.;Jutta H Hofmann.;Maria J Gasior.
来源: Rheumatology (Oxford). 2025年
The primary objective was the safety of subcutaneous immunoglobulin, IgPro20 (Hizentra, CSL Behring) in adults with diffuse cutaneous systemic sclerosis (dcSSc). Secondary objectives included pharmacokinetics and relative bioavailability of IgPro20, and safety and pharmacokinetics of intravenous immunoglobulin, IgPro10 (Privigen, CSL Behring).
385. Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry).
作者: Hirofumi Shoda.;Toshihiro Matsui.;Shigeto Tohma.;Tetsuji Sawada.
来源: Rheumatology (Oxford). 2025年
Patient-reported outcomes (PROs) should be regarded as an important factor in the management of rheumatic diseases. The Patient-based disease activity score (PDAS) was developed as a clinically reliable composite measure for evaluating PROs in rheumatoid arthritis (RA) patients. To replicate and further characterize PDAS, we analyzed PDAS and its clinical relevancy in the National Database of Rheumatic Diseases in Japan (NinJa).
387. Comment on: Renal arteriosclerosis in kidney biopsies associated with higher 10-year atherosclerotic cardiovascular disease in lupus nephritis: Reply.
作者: Shivani Garg.;Brad Rovin.;Amish N Raval.;Christie M Bartels.
来源: Rheumatology (Oxford). 2025年64卷5期3200-3201页 389. Faecal microbiota transplantation in patients with systemic sclerosis and lower gastrointestinal tract symptoms in Norway (ReSScue): a phase 2, randomised, double-blind, placebo-controlled trial.
作者: Håvard Fretheim.;Imon Barua.;Gunnstein Bakland.;Alvilde Dhainaut.;Anne-Kristine Halse.;Maylen N Carstens.;Henriette Didriksen.;Øyvind Midtvedt.;Knut E A Lundin.;Lars Aabakken.;Vikas K Sarna.;Hasse K Zaré.;Dinesh Khanna.;Oliver Distler.;Tore Midtvedt.;Espen S Bækkevold.;Inge C Olsen.;Diana Domanska.;Maiju E Pesonen.;Øyvind Molberg.;Anna-Maria Hoffmann-Vold.
来源: Lancet Rheumatol. 2025年7卷5期e323-e332页
Gastrointestinal tract involvement is highly prevalent in systemic sclerosis, with few treatment options. We assessed the efficacy and safety of faecal microbiota transplantation using standardised anaerobic cultivated human intestinal microbiome (ACHIM) as a novel treatment option for patients with systemic sclerosis and symptomatic lower gastrointestinal tract involvement.
390. Teledidactic peer-tutored musculoskeletal ultrasound training for medical students-the TELMUS study.
作者: Ricarda Neubauer.;Florian Recker.;Claus-Juergen Bauer.;Simon Petzinna.;Pantelis Karakostas.;Charlotte Behning.;Valentin Sebastian Schäfer.
来源: Rheumatology (Oxford). 2025年
Despite growing interest in musculoskeletal ultrasound (MSUS), training opportunities are often limited due to staff shortages and disbalances of expertise between rural and urban areas. Teledidactic approaches have the potential to expand access to training opportunities. This study aims to compare the effectiveness of teledidactic peer-tutored MSUS training to a conventional approach.
391. Tacrolimus as first line therapy in a U.S. cohort of idiopathic inflammatory myopathies related interstitial lung disease.
作者: Kamaree J R Harris.;Erica A Ludtke.;Blaire Goldberg.;Natalie N McCall.;Justin C Hewlett.;Erin M Wilfong.
来源: Rheumatology (Oxford). 2025年
Calcineurin inhibitors are commonly used to treat idiopathic inflammatory myopathies associated interstitial lung disease (IIM-ILD) in Asia but not in the U.S. Here, we evaluate the efficacy of tacrolimus (TAC) as first-line immunosuppressive therapy in a U.S cohort of IIM-ILD.
392. Association between large vessel vasculitis and inflammatory bowel disease: a case-control study.
作者: François Maillet.;Yann Nguyen.;Olivier Espitia.;Laurent Perard.;Carlo Salvarani.;Etienne Rivière.;Dieynaba Ndiaye.;Cécile-Audrey Durel.;Philippe Guilpain.;Luc Mouthon.;Anna Kernder.;Javier Loricera.;Pascal Cohen.;Isabelle Melki.;Claire de Moreuil.;Nicolas Limal.;Arsène Mékinian.;Nathalie Costedoat-Chalumeau.;Nathalie Morel.;Jonathan Boutemy.;Loïc Raffray.;Jean-Sébastien Allain.;Valérie Devauchelle.;Isabelle Kone-Paut.;Marc Fabre.;Marie Durel.;Antoine Dossier.;Sébastien Abad.;Marcella Visentini.;Adrien Bigot.;Halil Yildiz.;Olivier Fain.;Maxime Samson.;Guillaume Gondran.;Vered Abitbol.;Benjamin Terrier.
来源: Rheumatology (Oxford). 2025年
To describe the characteristics and outcome of patients with the association of large vessel vasculitis (LVV, Takayasu arteritis [TA] or giant cell arteritis [GCA]) and inflammatory bowel disease (IBD).
395. Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study.
作者: Kathleen M M Vanni.;Kaitlin R McCarter.;Xiaosong Wang.;Caitlyn Duffy.;Jamie P Dela Cruz.;Holly Wobma.;Sarah Nikiforow.;Elena M Massarotti.;Karen H Costenbader.;Jessica S Little.;Ellen M Gravallese.;Gregory C McDermott.;Caron A Jacobson.;Jeffrey A Sparks.
来源: Lancet Rheumatol. 2025年7卷4期e226-e229页 397. Incidence of ANCA associated vasculitis and polyarteritis nodosa in Norfolk, UK, from 2011-2020.
作者: Sarah Fordham.;Karen Ashurst.;Alice Bartoletti.;Fiona L Coath.;Georgina Ducker.;Ajay Kamath.;Warda Mushtaq.;Hassan Naeem.;Isabelle Nicholls.;Claire Sheehy.;Katherine Sisson.;Richard Watts.;Chetan B Mukhtyar.
来源: Rheumatology (Oxford). 2025年
To report the annual and age-specific incidence of ANCA associated vasculitis and polyarteritis nodosa in the adult population of Norfolk County, UK.
398. Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus.
作者: Sisi Yang.;Yuanyuan Zhang.;Ziliang Ye.;Yanjun Zhang.;Xiaoqin Gan.;Yu Huang.;Hao Xiang.;Yiting Wu.;Yiwei Zhang.;Xianhui Qin.
来源: Rheumatology (Oxford). 2025年
The relationship between proteomic profiles and incident systemic lupus erythematosus (SLE) remains unclear. We aimed to identify candidate plasma proteins for SLE risk in women, discover potential treatment targets for SLE, and develop and validate a protein-based prediction model for SLE risk.
|